BioCardia (BCDA) Net Income towards Common Stockholders (2010 - 2026)

BioCardia (BCDA) has reported Net Income towards Common Stockholders for 15 consecutive years, with -$1.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 20.87% year-over-year to -$1.6 million in Q2 2026; TTM through Jun 2026 was -$7.4 million, a 26.85% increase from a year earlier, with the FY2025 full-year figure at -$1.4 million, down 7.69% from the prior year.
• Net Income towards Common Stockholders was -$1.6 million for Q2 2026 at BioCardia, up from -$2.3 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$1.5 million in Q3 2025 and troughed at -$3.6 million in Q4 2024.
• A 5-year average of -$2.5 million and a median of -$2.5 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• The widest YoY moves for Net Income towards Common Stockholders: up 52.23% in 2024, down 73.75% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at -$3.0 million in 2022, then soared by 30.95% to -$2.1 million in 2023, then sank by 73.75% to -$3.6 million in 2024, then soared by 58.91% to -$1.5 million in 2025, then decreased by 9.07% to -$1.6 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$1.6 million (Q2 2026), -$2.3 million (Q1 2026), and -$1.5 million (Q3 2025), per Business Quant data.